Can smart monitoring predict dangerous side effects in blood cancer treatment?
NCT ID NCT06377059
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to find early signs that a patient is developing serious complications, like cytokine release syndrome, after immunotherapy for blood cancer. Researchers will track vital signs and immune responses in 100 adults receiving CAR-T or bispecific antibody therapy. The goal is to create a risk model that helps doctors decide who needs closer monitoring in the hospital.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRS - CYTOKINE RELEASE SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rigshospitalet
RECRUITINGCopenhagen O, 2100, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- 10,000 DNA samples could reveal hidden genetic triggers for leukemia and lymphoma
- Spirituality may be key to coping with blood cancer from day one
- App aims to get teens moving after beating blood cancer
- Talking away the tiredness: CBT tackles Post-Transplant fatigue
- Can zoom workouts help older cancer patients in the countryside?
- Music lessons from home might boost brain power in cancer survivors